Skip to content
Flyout Menu
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    • Discovery
      • CADD & Structural Biology
      • Compound Management
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vitro Biology
      • In Vivo Pharmacology
      • Integrated Drug Discovery (IDD)
      • Safety & Toxicology
      • Synthetic & Medicinal Chemistry
    • Drug Substance Development
      • Analytical Development
      • Developability & Pre-Formulation
      • Particle Science & Engineering
      • Process Development
      • Process Engineering
      • Discovery Process Chemistry
    • Drug Substance Manufacturing
      • Engineering Technologies
      • Infrastructure
      • Product Types
    • New Modalities
      • Antibody–Drug Conjugates
      • Lipids
      • Oligos
      • Peptides
    • Formulations
      • Clinical Formulation Supplies
      • New Chemical Entity (NCE) formulation development
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Newsroom – Blogs
    • Newsroom – Case Studies
  • Investors
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us

Sai Life Sciences joins the ACS Green Chemistry Institute Pharmaceutical Roundtable

26 Aug 2020

Sai Life Sciences today announced its induction to the ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS-GCIPR) as an ‘Associate Member’. The company has been committed to increasing the adoption of Green Chemistry principles in its process development and instituted its inaugural ‘Green Chemistry Awards’ last year, to recognize and celebrate teams that make notable contributions towards greener processes. Joining the ACS-GCIPR will allow the company to interact with large pharma and other CDMOs to further share and develop best practices in Green chemistry and sustainability

Welcoming Sai Life Sciences into its fold, an ACS-GCIPR spokesperson said, “The ACS GCI Roundtable is delighted to welcome Sai Life Sciences into its membership. As one of a few CDMO companies in our membership, their enthusiasm in catalysing the integration of green chemistry and engineering in the pharmaceutical industry is another heartening sign that adoption of Green Chemistry principles is indeed gaining momentum. We look forward to their active participation in the important work of the roundtable.”

Established in 2005 by the American Chemical Society’s Green Chemistry Institute, the Pharmaceutical Roundtable’s activities are driven by the shared belief that green chemistry and engineering is imperative for business and environmental sustainability. Its member companies come together to catalyse innovative approaches to improving process efficiency and product quality through green chemistry and engineering.

Over the past 18 months, Sai Life Sciences has made several enhancements to its HSE practices as part of the org-wide transformation initiative, Sai Nxt. Earlier this year, it became the first India-headquartered company to join the PSCI membership. The company also received 5-Star rating for Excellence in EHS Practices at the Confederation of Indian Industry (CII) South awards 2019. It operates a Zero Liquid Discharge cGMP manufacturing site in Bidar, India and has achieved zero waste to landfill.

Related News

Sai Life Sciences grows topline by 29% & doubles net profit in FY26

EBITDA up by 56%YoY; Net Profit up by 109%YoY Hyderabad, May 14, 2026: Sai Life Sciences Limited (BSE: 544306 I NSE: […]

28 May 2026

Sai Life Sciences becomes first Indian CRDMO with a site powered by 100% renewable energy

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development, and manufacturing organizations […]

28 May 2026

Sai Life Sciences recognized as Best Organization for Women (BOW) 2026 by ET Edge

Sai Life Sciences has been recognized as a Best Organization for Women (BOW) 2026 by ET Edge, reinforcing its continued […]

28 May 2026
1 / 45123Next Last

DS-7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India

Company
Main Menu
  • About Us
  • Investors
  • Careers
  • Contact us
Our Capabilities
Main Menu
  • Discovery
  • Drug Substance Development
  • Drug Substance Manufacturing
  • Formulations
  • New Modalities
Knowledge Hub
Main Menu
  • News
  • Blogs
  • Case Studies
Legal
Main Menu
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions

© 2026 Sai Life Sciences All rights reserved.

Facebook-f Instagram Linkedin-in X-twitter Youtube